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Background
Gastric cancer is the fourth most common cancer world-
wide. Despite advances in diagnosis of gastric cancer, the
prognosis at advanced stage of disease with the current
chemotherapeutic treatment strategies remains poor.
Hence, new agents and molecular targets for gastric cancer
therapy are desperately needed. Sphingosine kinase 1 rep-
resents a promising novel target for anti-cancer therapy.
However, the most common used small molecule inhibi-
tors of SphK are unspecific inhibitors of SphK1. Here we
investigated the effect of targeted downregulation of
SphK1 by locked nucleic acid antisense oligonucleotides
(LNA-ASO) in gastric cancer cell lines.
Materials and methods
MKN28 and NCI-N87 gastric cancer cell lines were
assessed for cell proliferation and cell death electronic cell
counting and FACS analysis, respectively. Target modula-
tion of Sphk1 mRNA was assessed by real-time reverse
transcriptase PCR. For combination therapy, Sphk1 LNA-
ASO was combined with doxorubicin and analyzed for
cell growth and apoptosis.
Results
LNA-ASO targeting SphK1 reduced SphK1 mRNA levels in
a dose dependent manner (1.9–4.9-fold) whereas the
control LNA-ASO did not lower Sphk1 mRNA levels at all.
We next assessed the biological relevance of SphK1 down-
regulation by LNA with respect to anti-proliferative activ-
ity. Following transfection with 12.5 nM Sphk1 LNA-ASO
we observed growth inhibition of MKN28 gastric cancer
cells (up to 57%) beginning from 24 h after transfection.
Notably, the combination of Sphk1 LNA-ASO with doxo-
rubicin resulted in significant chemosensitizing anti-pro-
liferative activity. The anti-tumor activity coincided with
an increase in the number of apoptotic cells both in the
monotherapy and in the combination group as deter-
mined by FACS analysis.
Conclusion
SphK1 target downregulation induces apoptosis and
reduces cell counts of gastric cancer cells indicating a role
for SphK1 as a functional relevant molecular target in gas-
tric cancer cells. Moreover, downregulation of SphK1 sen-
sitizes gastric cancer cells to doxorubicin. Our data
provide a sound rationale for in vivo studies of SphK1 LNA
ASO as novel and promising strategy against gastric can-
cer.
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